ArticleFrontiers in neuroscience2026
Amygdala subregional atrophy across ATN-defined Mild Cognitive Impairment subgroups.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum.Neuroimage. Reports · 2026Article
- The Amygdala and Politics.Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) pathology begins years before clinical symptoms, with Mild Cognitive Impairment (MCI) as a prodromal stage. The ATN framework (Amyloid, Tau, Neurodegeneration) aids in stratifying MCI risk. While amygdala atrophy is a recognized biomarker, amygdala subregional changes across ATN-defined MCI subgroups remain underexplored. Methods: This study analyzed MRI data and cerebrospinal fluid biomarkers from 134 MCI participants classified into A-T-, A+T-, and A+T+ subgroups. The volumes of amygdala subregions were computed and compared among the different groups. Furthermore, we also investigated the relationship between the altered brain regions and cognitive function. Results: Significant atrophy was observed in the A+T+ group within bilateral basal, accessory basal, central nuclei, and right cortical-amygdaloid transition area compared to other groups. Volume reductions in the left central nucleus correlated positively with cognitive scores. Conclusion: Amygdala subregional atrophy, particularly in the central, basal, accessory basal, and cortical-amygdaloid transition nuclei, is linked to AD pathology progression and cognitive decline. The findings suggest a potential vulnerability of the right amygdala and suggest these subregions may be associated with AD-related pathological progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.